Summary. Background: Markers of thrombosis, inflam- mation, endothelial dysfunction and neurohumoral acti- vation such as fibrinogen, D-dimer, C-reactive protein, von Willebrand factor, tumour necrosis factor-alpha and chromogranin-A are reported to be linked to the increase of cardiovascular risk for atherosclerosis progression and events in patients with cardiovascular diseases. Methods: EUROPA is a double blind, placebo-controlled trial on 12231 patients that evaluates the effect of an angiotensin converting enzyme inhibitor—perindopril—on prevention of cardiovascular events in patients with coro- nary artery disease. PERTINENT is a sub-study of EUROPA that evaluates (a) in Part A (300 patients): the influence of perindopril vs. placebo on fibrinogen, D-dimer, C-reactive protein, von Willebrand factor, tumour necrosis factor-alpha and chromogranin-A. In addition, NOS expression and in- duction of apoptosis on human umbilical vein endothelial cells and angiotensin converting enzyme levels are also studied; (b) in Part B (about 1200 patients): the predictive role of plasma levels of C-reactive protein and von Wille- brand factor on the occurrence of cardiovascular events. To this end, matched case-control analyses are planned (pa- tients with vs. patients without events). Status of PERTINENT: Blood analyses are in progress in four specialised laboratories: (a) Gaubius Laboratory, Leiden, TNO-PG, The Netherlands; (b) University Depart- ment of Medicine, Birmingham, UK; (c) University of Pavia, Italy; (d) Fondazione Salvatore Maugeri, Cardiovascular Research Centre, Gussago, Italy. Conclusions: The PERTINENT sub-study might help elu- cidating the phenomena contributing to the pathophysi- ology of cardiovascular events in patients with coronary artery disease and the role of perindopril in such context.
Pertinent / Ferrari, R; Arbustini, E; Blann, A; Cokkinos, D; Kluft, C; de Maat, Mpm; Tavazzi, L; Christakos, S; Cokkinos, D; Geleris, P; Gialafos, J; Kardaras, F; Karidis, K; Kelesides, C; Koliopolos, N; Pyrgakis, V; Stamatelopoulos, S; Stavridis, A; Syribeis, S (Patras); Vardas, P (Iraklion); Vassiliadis, J; Zacharoulis, A; Zobolos, S; Manolis, A; Giannetto, M; Azzolini, P; Bellone, E; Pela', G; Brunelli, C; Capponi, E; Casaccia, M; Ceci, V; Corsini, G; De Luca, I; De, ; Servi, S; Guarnerio, M; Di Pasquale, G; Fiorentini, C; Giannuzzi, P; Giovannini, E; Sinagra, Gf; Pettinati, G; Polimeni, Mr; Santini, M; Tantalo, L; Tavazzi, L; Vajola, S; Di Giacomo, U; Gaddi, O; Iacono, A; Riva, S; Cappucci, A; Marinoni, Gp; Inama, G; Antolini, R; Celegon, L; Sanguinetti, M; Cucchini, F; Renaldini, E; Giordano, A; Papi, S; Marzilli, M; Dalla Volta, S; Volterrani, M; Portaluppi, F; Lorusso, R; Di Donato, M; Colombo, A; Branzi, A; Proto, C; Leghissa, R; Ferrera, R; Leitao Marques, A; dos Santos Andrade, Cm; Guallar Urena, C; Aguirre Salcedo, Jm; Ancilla Garcia, P; Ayuela Azcarate, J; Bertomeu Martinez, V; Blanco Coronado, Jl; Bruguera Cortada, J; Paz Barmejo, M; Espinosa Calini, Js; Alonso Horcajo, N; Garcia Guerrero, Jj; Jodar Lorente, L; Maroto Montero, Jm; Martinez Romero, P; Bardaji Mayor, Jl; Navarro Lopez, F; Noriega Peiro, F; Olague de Ros, J; Orellana Mas, J; Caparros Valderrama, J; Garcia Lopez, D; Salvador Sanz, A; Segui Bonnin, J; Simarro, E; Valles Belsue, F; Bros Caimani, R; Lopez Garcia Aranda, V; del Rio Ligorit, A; Gonzalez Cocina, E; Macaca Miguel, C; Auge Sanpera, Jm. - In: CARDIOVASCULAR DRUGS AND THERAPY. - ISSN 1573-7241. - 17(2003), pp. 83-91. [10.1023/a:1024394610648]
Pertinent
Pela' G;
2003-01-01
Abstract
Summary. Background: Markers of thrombosis, inflam- mation, endothelial dysfunction and neurohumoral acti- vation such as fibrinogen, D-dimer, C-reactive protein, von Willebrand factor, tumour necrosis factor-alpha and chromogranin-A are reported to be linked to the increase of cardiovascular risk for atherosclerosis progression and events in patients with cardiovascular diseases. Methods: EUROPA is a double blind, placebo-controlled trial on 12231 patients that evaluates the effect of an angiotensin converting enzyme inhibitor—perindopril—on prevention of cardiovascular events in patients with coro- nary artery disease. PERTINENT is a sub-study of EUROPA that evaluates (a) in Part A (300 patients): the influence of perindopril vs. placebo on fibrinogen, D-dimer, C-reactive protein, von Willebrand factor, tumour necrosis factor-alpha and chromogranin-A. In addition, NOS expression and in- duction of apoptosis on human umbilical vein endothelial cells and angiotensin converting enzyme levels are also studied; (b) in Part B (about 1200 patients): the predictive role of plasma levels of C-reactive protein and von Wille- brand factor on the occurrence of cardiovascular events. To this end, matched case-control analyses are planned (pa- tients with vs. patients without events). Status of PERTINENT: Blood analyses are in progress in four specialised laboratories: (a) Gaubius Laboratory, Leiden, TNO-PG, The Netherlands; (b) University Depart- ment of Medicine, Birmingham, UK; (c) University of Pavia, Italy; (d) Fondazione Salvatore Maugeri, Cardiovascular Research Centre, Gussago, Italy. Conclusions: The PERTINENT sub-study might help elu- cidating the phenomena contributing to the pathophysi- ology of cardiovascular events in patients with coronary artery disease and the role of perindopril in such context.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
